{"id":"perampanel-oral-tablet","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Somnolence"},{"rate":"10-15","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Irritability"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Aggression"},{"rate":"5-10","effect":"Weight gain"}]},"_chembl":{"chemblId":"CHEMBL1214124","moleculeType":"Small molecule","molecularWeight":"349.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Perampanel selectively blocks AMPA-type glutamate receptors on the postsynaptic membrane, which are key mediators of excitatory synaptic transmission. By antagonizing these receptors, it reduces neuronal hyperexcitability and abnormal electrical activity associated with seizures. This mechanism differs from other antiepileptic drugs and provides an additional treatment option for patients with inadequate seizure control on existing therapies.","oneSentence":"Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:40:52.001Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Adjunctive treatment of partial-onset seizures in patients 12 years of age and older"},{"name":"Adjunctive treatment of primary generalized tonic-clonic seizures in patients 12 years of age and older"}]},"trialDetails":[{"nctId":"NCT04015141","phase":"PHASE2","title":"A Study to Evaluate Efficacy and Safety of Perampanel Administered as an Adjunctive Therapy in Pediatric Participants With Childhood Epilepsy","status":"RECRUITING","sponsor":"Eisai Inc.","startDate":"2019-05-31","conditions":"Pediatric Epileptic Syndrome, Partial-onset Seizures","enrollment":100},{"nctId":"NCT02307578","phase":"","title":"An Extended Access Program (EAP) for Perampanel","status":"NO_LONGER_AVAILABLE","sponsor":"Eisai Inc.","startDate":"","conditions":"Primary Generalized Tonic-Clonic or Partial Onset Seizures, Lennox Gastaut Syndrome","enrollment":""},{"nctId":"NCT05533814","phase":"PHASE4","title":"A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2022-10-19","conditions":"Epilepsy","enrollment":125},{"nctId":"NCT04497142","phase":"PHASE1, PHASE2","title":"Effect of Perampanel on Peritumoral Hyperexcitability in HGG","status":"COMPLETED","sponsor":"Dana-Farber Cancer Institute","startDate":"2020-11-05","conditions":"Glioma, Malignant, Surgery, Seizures","enrollment":12},{"nctId":"NCT06450223","phase":"PHASE1","title":"Bioequivalence Study of Perampanel Tablets 12 mg","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2023-09-14","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT06450236","phase":"PHASE1","title":"Bioequivalence Study of Perampanel Tablets 10 mg","status":"COMPLETED","sponsor":"Humanis Saglık Anonim Sirketi","startDate":"2023-11-22","conditions":"Epilepsy","enrollment":30},{"nctId":"NCT03793868","phase":"EARLY_PHASE1","title":"Perampanel Single Ascending Dose Transcranial Magnetic Stimulation Biomarker Study in Amyotrophic Lateral Sclerosis","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2018-12-04","conditions":"Amyotrophic Lateral Sclerosis","enrollment":22},{"nctId":"NCT04309721","phase":"PHASE3","title":"Perampanel in Focal Status Epilepticus","status":"TERMINATED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2022-11-02","conditions":"Epilepticus; Status, Focal Motor","enrollment":1},{"nctId":"NCT03457129","phase":"PHASE4","title":"Fycompa Titration Intervals and Effects on Retention Rate","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2018-04-18","conditions":"Epilepsy","enrollment":20},{"nctId":"NCT04202159","phase":"","title":"A Study to Evaluate the Effectiveness of Perampanel as Only Add-on Treatment in Participants With Primary or Secondarily Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai GmbH","startDate":"2020-01-21","conditions":"Seizures","enrollment":187},{"nctId":"NCT03020797","phase":"NA","title":"A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS)","status":"TERMINATED","sponsor":"Stony Brook University","startDate":"2017-01-12","conditions":"Amyotrophic Lateral Sclerosis","enrollment":12},{"nctId":"NCT04252846","phase":"","title":"A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2020-07-20","conditions":"Idiopathic Generalized Epilepsy, Partial Onset Seizures, Generalised Tonic-Clonic Seizures","enrollment":191},{"nctId":"NCT03059381","phase":"","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adolescence Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-08-01","conditions":"Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures","enrollment":519},{"nctId":"NCT03288129","phase":"PHASE4","title":"Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-08-23","conditions":"Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures","enrollment":54},{"nctId":"NCT03059329","phase":"","title":"Investigation of the Clinical Safety and Efficacy of Long-term Treatment With Fycompa Tablets in Adult Epilepsy Patients With Partial-onset Seizures (With or Without Secondary Generalized Seizures) or Primary Generalized Tonic-clonic Seizures","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-08-01","conditions":"Partial Seizures (With or Without Secondary Generalized Seizures), Primary Generalized Tonic-clonic Seizures","enrollment":3809},{"nctId":"NCT02722590","phase":"","title":"A Study of Fycompa (Perampanel) in Korean Participants","status":"COMPLETED","sponsor":"Eisai Korea Inc.","startDate":"2016-07-01","conditions":"Epilepsy","enrollment":3692},{"nctId":"NCT03201900","phase":"PHASE3","title":"Study for Verification of Efficacy and Safety for Perampanel Monotherapy in Untreated Participants With Partial Onset Seizures (Including Secondarily Generalized Seizures (FREEDOM Study)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-06-28","conditions":"Partial Onset Seizures","enrollment":91},{"nctId":"NCT03836924","phase":"","title":"A Study to Assess Safety and Efficacy of Perampanel in Indian Participants as an Adjunctive Treatment in Partial Onset Seizures With or Without Secondary Generalized Seizures in Participants With Epilepsy Aged 12 Years or Older","status":"COMPLETED","sponsor":"Eisai Pharmaceuticals India Pvt. Ltd","startDate":"2019-02-18","conditions":"Partial Onset Seizures, Epilepsy","enrollment":200},{"nctId":"NCT03754582","phase":"PHASE2","title":"A Study of Intravenous Perampanel in Japanese Participants With Epilepsy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2018-11-27","conditions":"Epilepsy, Seizures","enrollment":21},{"nctId":"NCT01871233","phase":"","title":"An Extended Access Program for Perampanel","status":"NO_LONGER_AVAILABLE","sponsor":"Eisai Inc.","startDate":"","conditions":"Partial Onset Seizures","enrollment":""},{"nctId":"NCT02131467","phase":"PHASE1, PHASE2","title":"Safety and Tolerability of Perampanel in Cervical Dystonia","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2017-09-01","conditions":"Cervical Dystonia","enrollment":25},{"nctId":"NCT04257604","phase":"","title":"A Study of Perampanel as Add-on Therapy in Adult and Adolescent Participants With Focal Seizures","status":"COMPLETED","sponsor":"Eisai Limited","startDate":"2016-01-03","conditions":"Partial Seizures","enrollment":243},{"nctId":"NCT04230044","phase":"","title":"A Study to Evaluate the Safety and Efficacy of Fycompa® (Perampanel) as Add-on Therapy in Participants With Epilepsy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2016-04-11","conditions":"Epilepsy, Partial-onset Seizures","enrollment":117},{"nctId":"NCT03780907","phase":"PHASE2","title":"Safety and Pharmacokinetics Study of E2007 to Treat Partial and Generalised Seizures in People With Epilepsy","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2003-02-14","conditions":"Epilepsy","enrollment":18},{"nctId":"NCT03399734","phase":"PHASE1","title":"Bioequivalence Study Between a 4-mg Dose of Fine Granules of Perampanel and a 4-mg Tablet of Perampanel in Healthy Japanese Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2017-12-18","conditions":"Healthy Participants","enrollment":24},{"nctId":"NCT03376997","phase":"PHASE1","title":"Study to Evaluate Bioavailability of a Single 12 mg Dose of Perampanel for Three Intravenous Infusion Durations Relative to a Single 12 mg Perampanel Oral Tablet in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2017-11-08","conditions":"Healthy Participants","enrollment":48},{"nctId":"NCT02033902","phase":"","title":"A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-06-06","conditions":"Epilepsy","enrollment":500},{"nctId":"NCT00903786","phase":"PHASE2","title":"A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2009-06-17","conditions":"Refractory Partial Seizures","enrollment":21},{"nctId":"NCT03424564","phase":"PHASE1","title":"Pharmacokinetic Study of Perampanel in Chinese Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2018-03-20","conditions":"Healthy Subjects","enrollment":44},{"nctId":"NCT02279485","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between a 12-mg Dose of an Oral Suspension Formulation of Perampanel and a 12-mg Tablet Formulation of Perampanel Under Fasted and Fed Conditions in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2014-09","conditions":"Healthy Subjects","enrollment":100},{"nctId":"NCT02020486","phase":"PHASE1","title":"A Multiple Dose Pharmacokinetic Study of Perampanel in Korean Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Co., Ltd.","startDate":"2013-12","conditions":"Healthy","enrollment":20},{"nctId":"NCT00505284","phase":"PHASE2, PHASE3","title":"An Evaluation of the Efficacy and Safety of E2007 in Patients With Painful Diabetic Neuropathy","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2007-06","conditions":"Diabetic Neuropathy","enrollment":352},{"nctId":"NCT01240187","phase":"PHASE1","title":"A Study to Demonstrate Bioequivalence Between 6 x 2 mg Tablets of Perampanel and a Single 12 mg Tablet of Perampanel in Healthy Subjects","status":"COMPLETED","sponsor":"Eisai Inc.","startDate":"2010-06","conditions":"Partial Onset Epilepsy","enrollment":22},{"nctId":"NCT00427011","phase":"PHASE2","title":"A Study of E2007 In Patients With Parkinson's Disease","status":"TERMINATED","sponsor":"Eisai Inc.","startDate":"2007-02","conditions":"Parkinson's Disease","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Fycompa","E2007"],"phase":"marketed","status":"active","brandName":"Perampanel Oral Tablet","genericName":"Perampanel Oral Tablet","companyName":"University of Arizona","companyId":"university-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Perampanel is a non-competitive AMPA receptor antagonist that reduces glutamate-mediated excitatory neurotransmission in the brain. Used for Adjunctive treatment of partial-onset seizures in patients 12 years of age and older, Adjunctive treatment of primary generalized tonic-clonic seizures in patients 12 years of age and older.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}